Adicet Bio, Inc.
NASDAQ:ACETBiotechnology
+$0.02 today
- Market cap
- $51.70M
- Beta
- 1.57
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$10.13
Volume 0.15M
Average 0.12M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Adicet Bio, Inc.
NASDAQ:ACET
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Immunic, Inc. NASDAQ:IMUX | $127.29M | $9.35 | Not rated | -4.1 | +7.41% |
Adagene Inc. NASDAQ:ADAG | $110.31M | $2.93 | Not rated | -7.9 | +13.56% |
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | $89.88M | $2.10 | Not rated | -0.8 | -38.05% |
Gain Therapeutics, Inc. NASDAQ:GANX | $75.92M | $1.78 | Not rated | -3.6 | -58.60% |
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | $51.77M | $3.00 | Not rated | -5.3 | +25.62% |
Werewolf Therapeutics, Inc. NASDAQ:HOWL | $46.65M | $0.96 | Not rated | -1.4 | +20.51% |
TScan Therapeutics, Inc. NASDAQ:TCRX | $20.77M | $0.34 | Not rated | -1.0 | -16.29% |
Continue the stock analysis
Jump to another research area for this company.